The wearable injectors market is expected to grow significantly, from USD 6.7 billion in 2022 to USD 20.9 billion by 2032, at a compound annual growth rate (CAGR) of 12.4% during the forecast period ...

Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.

Amgen Inc (NASDAQ:AMGN) has recently announced a dividend of $2.25 per share, set to be payable on June 7, 2024, with the ...

The global biopharmaceuticals market is poised for significant growth, with its value expected to reach USD 566 billion by ...

On February 15, 2024, the Company completed an underwritten public offering for gross proceeds of approximately $10 million. The net proceeds received by the Company were $8,522,411. 'We continue to ...

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant ...

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ: AMGN). Both stocks have been in the limelight lately, given their focus on the ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer ...